Long-Acting Cabenuva Maintains Suppression in Patients With Prior Adherence Challenges

Originally published by our sister publication Infectious Disease Special EditionBy Ethan CoveyLong-acting injectable cabotegravir plus rilpivirine (CAB/RPV-LA; Cabenuva, ViiV Healthcare) remained noninferior to daily oral dolutegravir-based antiretroviral therapy (ART) through 96 weeks among people with a history of treatment adherence or care-engagement challenges, according to results from the IMPALA trial presented at AIDS 2026, in Rio de Janeiro (poster LB24).figure { display:inline-block;